Two-Year Outcomes after Transcatheter or Surgical Aortic-Valve Replacement

20122,277 citationsJournal Articlebronze Open Access

Authors

Susheel Kodali · Columbia University Irving Medical Center

Mathew Williams · New York Hospital Queens

Craig R. Smith · Columbia University Irving Medical Center

Lars G. Svensson · Cleveland Clinic

John G. Webb · University of British Columbia

Raj Makkar · Cedars-Sinai Medical Center

Gregory P. Fontana

Abstract

A 2-year follow-up of patients in the PARTNER trial supports TAVR as an alternative to surgery in high-risk patients. The two treatments were similar with respect to mortality, reduction in symptoms, and improved valve hemodynamics, but paravalvular regurgitation was more frequent after TAVR and was associated with increased late mortality. (Funded by Edwards Lifesciences; ClinicalTrials.gov number, NCT00530894.).

Topics & Keywords

Cardiac Valve Diseases and Treatments Infective Endocarditis Diagnosis and Management Cardiac Imaging and Diagnostics

Publication Details

Published in: New England Journal of Medicine

Volume 366, Issue 18, pp. 1686-1695

DOI: 10.1056/nejmoa1200384

Field-Weighted Citation Impact: 191.84

Command Palette

Two-Year Outcomes after Transcatheter or Surgical Aortic-Valve Replacement

Authors

Abstract

Topics & Keywords

Publication Details